SCHEMBL454756

SCHEMBL454756

O=C(O)c1ccc(F)cc1C1CCCN1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 1/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAG3 Q9UGI9 1/20 0.40
PRKAG2 Q9UGJ0 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40
KEAP1 Q14145 1/20 0.39
PARP1 P09874 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KCNH2 Q12809 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
KDM4C Q9H3R0 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21835399 1.00 PRKAB2 (0.40) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL28923701 0.84 PARP1 (0.42) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24233561 0.83 MEN1 (0.43) PARP1MEN1KMT2AKCNH2KDM4E
SCHEMBL24801643 0.83 CREBBP (0.47) PARP1MEN1KMT2AL3MBTL1KCNH2
Oxalic Acid SCHEMBL28871384 0.82 HCAR2 (0.40) PARP1MEN1KMT2AKCNH2PTGDR2
Oxalic Acid SCHEMBL28871386 0.82 HCAR2 (0.40) PARP1MEN1KMT2AKCNH2PTGDR2
SCHEMBL21494180 0.78 HTR2A (0.41) MEN1KMT2AKCNH2
SCHEMBL21319565 0.78 MEN1 (0.41) MEN1KMT2AL3MBTL1KCNH2
SCHEMBL21494179 0.78 HTR2A (0.41) MEN1KMT2AKCNH2
SCHEMBL28452039 0.78 PARP1 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220033402-A1 MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-03 US disclosed
EP-3856745-A1 MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 Dana Farber Cancer Institute, Inc. (US) 2021-08-04 EP disclosed
WO-2020069118-A1 MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-02 WO disclosed
WO-2012034095-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 WO disclosed
WO-2012034095-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033402-A1 MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 ROS1, ALK, NTRK3 PRKAB2 425/4885PRKAG1 198/4885PRKAA2 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.